Society for Immunotherapy of Cancer Announces $450,000 in Cancer Immunotherapy Fellowships for Early Career Scientists
PRWeb
FacebookTwitterEmail
The Society for Immunotherapy of Cancer (SITC) is dedicated to supporting the next generation of cancer immunotherapy experts through dedicated funding of novel research. SITC is pleased to offer domestic and international early career investigators in academia and government four fellowships opportunities, totaling $450,000 in funding.
MILWAUKEE (PRWEB) February 10, 2021
The Society for Immunotherapy of Cancer (SITC) is dedicated to supporting the next generation of cancer immunotherapy experts through dedicated funding of novel research. SITC is pleased to offer domestic and international early career investigators in academia and government four fellowships opportunities, totaling $450,000 in funding.
Share this article
Share this article
DUBLIN, Feb. 11, 2021 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter and year ended Dec. 31, 2020 and provided financial expectations for 2021. 2020 was a demonstration of the resiliency of our organization, as we adapted our business to endure a pandemic that has proved to be one of the most disruptive events in our recent history. Despite the challenges posed by COVID-19, we achieved significant growth of net sales from our portfolio of proprietary commercial products, advanced our pipeline of neuroscience and oncology candidates, and announced a Value Enhancement Plan designed to drive growth and improve operational and financial performance, said Richard Pops, Chief Executive Officer of Alkermes. We are focused on value creation in 2021 as we seek to grow and diversify our commercial portfolio, demonstrate the value of our R&D investments, and manage the company for growth and long-term pr
Jeanne Zucker Joins PlatformQ Health as SVP Strategic Alliances
Share Article
PlatformQ Health deepens its expertise in creating innovative, far-reaching, and impactful educational programs.
“I’m thrilled to join an organization with such a rich history of partnerships and collaborations in healthcare,” said Zucker. BOSTON (PRWEB) February 10, 2021 PlatformQ Health, the leading digital provider of medical education, announced that Jeanne Zucker joined the company as Senior Vice President of Strategic Alliances, where she will oversee PlatformQ Health’s strategic educational partnerships with key healthcare organizations and trusted medical institutional leaders.
“I’m thrilled to join an organization with such a rich history of partnerships and collaborations in healthcare,” said Zucker. “PlatformQ Health has such a unique opportunity to support educational goals by working with key organizations
Longevity Acquisition Corporation Announces 4D pharma Update on Oncology Program
News provided by
Share this article
Share this article
NEW YORK, Feb. 3, 2021 /PRNewswire/ Longevity Acquisition Corporation (NASDAQ: LOAC) (the Company ), a publicly-traded special purpose acquisition company, announced today that on February 3, 2021, 4D pharma plc (AIM: DDDD) ( 4D pharma ), a pharmaceutical company leading the development of Live Biotherapeutic products ( LBPs ) - a novel class of drug derived from the microbiome, and a business combination target of LOAC, has announced progress on activities in its development program for lead immuno-oncology single strain Live Biotherapeutic candidate MRx0518. 4D pharma has continued to make excellent progress with the MRx0518 development program on multiple fronts. We have generated additional safety and efficacy data, building on the positive data from both the monotherapy and KEYTRUDA combination studies last year. This clinical and devel
Amgen Reports Fourth Quarter And Full Year 2020 Financial Results
News provided by
Share this article
Share this article
THOUSAND OAKS, Calif., Feb. 2, 2021 /PRNewswire/ Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2020 versus comparable periods in 2019. Key results include:
For the fourth quarter, total revenues increased 7% to $6.6 billion in comparison to the fourth quarter of 2019, driven by higher volume growth, partially offset by lower net selling prices.
Product sales increased 8% globally, driven by 13% volume growth across the portfolio, including Otezla
® (apremilast), MVASI
® (trastuzumab-anns), and Repatha
® (evolocumab), partially offset by declines in mature products that resulted from biosimilar and generic competition.